Navigation Links
An Expanding Patient Pool And Technological Innovation Will Drive Moderate Growth In The US Market For Biopsy Devices
Date:8/14/2013

TORONTO, Aug. 14, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for biopsy devices will see moderate growth through 2021, driven in part by the aging and increasingly obese population. These demographic groups are at an increased risk of developing diseases such as cancer, and they will therefore drive demand for biopsies when anomalies are detected. In addition, increased public awareness regarding diseases and screening guidelines has led to higher biopsy volumes for patients outside of the aforementioned patient pool.

Innovations in imaging technology have greatly improved image quality and detail, especially for the gastrointestinal (GI) tract and bronchial structures. As visualization equipment provides physicians with higher resolution and more magnified images of the human body, biopsies will become more targeted and precise. As a result, physicians will become increasingly confident in the ability of these systems to accurately locate areas requiring examination, thereby supporting procedure volume expansion.

"Most segments of the US biopsy device market are also seeing a shift toward disposable biopsy devices," said MRG Analyst Jason Lau. "Disposable units offer greater convenience to physicians because they do not require sterilization after each use. Greater adoption of disposable devices will mean that there will be a larger volume of units sold, leading to greater market growth. However, this trend will be less prevalent in private practice or high-volume facilities, where cost-conscious physicians and central sterilization departments continue to make reusable devices, especially forceps, a cost-effective option."

The gynecological biopsy device market will be somewhat negatively affected in the near future by the human papillomavirus (HPV) vaccine, which first became available for adolescents in June 2006. According to the Centers for Disease Control and Prevention, HPV is the cause for nearly all incidents of cervical cancer, which generally develops in women over the age of 30. Although not mandatory, many adolescents have received the vaccine in order to decrease future risk of cervical cancer. Therefore, it is expected that as the current generation of adolescents approaches the at-risk age, the effects of the vaccination will result in a decline in cervical cancers, thus necessitating fewer cervical biopsies.

Millennium Research Group's US Markets for Biopsy Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for breast biopsy devices, GI biopsy devices, soft tissue biopsy needles, bronchial biopsy devices and gynecological biopsy devices in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
2. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
5. Wound Care Management Market to 2018 - Advanced Wound Care Modalities and an Expanding Patient Base Create Significant Growth Opportunities in Emerging Countries
6. Positioning Strategies Effectively Minimize Cannibalization of a Legacy Brand When Expanding a Product Portfolio
7. UBM Canon, the Global Authority on the MedTech Industry, Announces Key Hire in Germany to Complement Its Expanding Media and Marketing Solutions Team
8. Medical Devices Market in China to 2018 - Government Reforms Aimed at Strengthening the Healthcare System and Expanding Access will Accelerate Growth
9. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
10. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
11. Westpak Is Expanding HAZMAT Testing To Meet Demand From The Medical Device Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):